# PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer

> **NCT05033392** · PHASE2 · RECRUITING · sponsor: **Wan He** · enrollment: 62 (estimated)

## Conditions studied

- Stomach Neoplasms

## Interventions

- **DRUG:** Toripalimab Injection

## Key facts

- **NCT ID:** NCT05033392
- **Lead sponsor:** Wan He
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-09-14
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2025-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05033392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05033392, "PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05033392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*